Personalized medicine for kidney disease: can genes predict who will respond?

NCT ID NCT07416942

Not yet recruiting Knowledge-focused Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find genetic and protein markers that can predict whether patients with membranous nephropathy, a kidney disease, will respond to the drug rituximab. Researchers will analyze stored blood and tissue samples from 120 patients and healthy volunteers. The goal is to develop a personalized approach to treatment, avoiding ineffective therapies and their side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors choose the right treatment for membranous nephropathy patients, improving outcomes and reducing side effects.
What could go wrong: This is an observational study on stored samples, not a treatment trial. The findings may not lead to immediate clinical changes or may not be confirmed in future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEMBRANOUS NEPHROPATHY

Contacts and locations

Locations

Clinical Research Centre for Rare Diseases Aldo e Cele Daccò

Ranica, BG, 24020, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.